NCT01425749 - Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2015

Conditions

Melanoma

Interventions

BIOLOGICAL

recMAGE-A3 + AS15 ASCI

Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.

Trial Locations (1)

22908

University of Virginia, Charlottesville